Wision A.I. Expands U.S. Offerings to Combat Colorectal Cancer With Multiple Screening Tools

Wision A.I. Ltd. has announced the expansion of its product portfolio with recent U.S. FDA 510(k) Clearance for EndoScreener, its AI-assisted polyp detection software during colonoscopy.


Shanghai-based Wision A.I. Ltd., is a startup in the field of artificial intelligence assisted diagnostics for optical medical imaging. The company claims extensive expertise in mathematics and algorithm development. It integrates medical knowledge into flexible and scalable models that leverage cutting-edge, convolutional neural networks and general-purpose computing to achieve stable detection efficacy in diagnostic imaging.

In addition to its 510(k) clearance, the company also has an FDA presubmission in queue for an upcoming histopathology AI software that assists in the localization of high-grade dysplasia (HGD) in whole slide imaging (WSI).

According to the American Cancer Society, colorectal cancer (CRC) is the second most common cancer in men and women combined and is expected to cause over 50,000 deaths in 2022. Detection and removal of adenomatous polyps at early diagnosis and regular colonoscopy screening are the most effective ways to reduce the incidence and mortality of CRC. Following the data publication surrounding the first external independent randomized controlled trial (RCT) of AI in the United States, in November 2021, the FDA granted 510(k) Clearance for EndoScreener, Wision A.I.’s AI-assisted polyp detection software. The software-only medical device increased detected adenoma by 32.2% and reduced adenoma miss rate by 35.6% in a multi-center randomized controlled trial conducted by four U.S. leading academic medical centers.

The Centers for Disease Control (CDC) estimates that by 2024, there should be approximately 11 to 13 million annual colonoscopies needed to screen the eligible patient population. The emergence of AI, as well as other endoscopic technologies, is proven to considerably increase polyp detection and removals per colonoscopy. Wision A.I.’s new histopathological AI product is used to localize HGD, the cancerous characteristics, in histologic whole slide imaging (WSI) for colorectal specimens. Through this technique, a precise histological diagnosis is used to determine a patient’s risk and surveillance interval, identifying high-risk signs that lead to interval CRC. The incorporation of AI improves efficiency during histopathological diagnosis by saving the pathologist time to determine the correct diagnosis for each patient.

Company comments

“Obtaining 510(k) Clearance from the FDA for EndoScreener and initiating a U.S. based investigational validation of the new tool for histopathological diagnosis demonstrates how our broadened, enriched AI portfolio can help to reduce colorectal cancer and improve patient outcomes,” stated JingJia Liu, co-founder and Chief Executive Officer of Wision A.I.

“This announcement comes at a pivotal time during Colorectal Cancer Awareness Month, where we are working towards optimizing CRC detection through new, efficient, and precise methods. We believe that AI polyp detection in colonoscopy and AI HGD localization in histological diagnosis will greatly synergize and contribute to CRC screening and prevention.”

Source: Globenewswire

Share your thoughts

Your email address will not be published. Required fields are marked *